Your genes could guide your pain meds: new study tests personalized prescribing

NCT ID NCT06511401

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving doctors genetic information about their patients can help them choose safer and more effective pain medications. Researchers will enroll 800 cancer patients who are expected to need opioid painkillers. Half will have their genes tested to guide prescribing, while the other half will receive standard care. The goal is to see if the genetic approach leads to better pain control and fewer medication changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pharmacogenomic (PGx) testing
What this could lead to
If successful, this could show that using a person's genetic information helps doctors pick the right pain medicine and dose, leading to better pain control with fewer side effects.
What could go wrong
This is an early-stage study (Phase N/A) with 800 participants. It's testing a process, not a new drug, so the direct benefit to patients may be small or unclear. Results may not apply to all cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WHO ARE RECEIVING ONCOLOGIC CARE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.